6月16日，Abivax S.A.盘中上涨5.03%，报101.41美元/股，成交额7746.5万美元。
消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例引发股价自130美元附近暴跌至约70美元，跌幅一度近50%。但市场对安全性数据的恐慌情绪逐步消化：试验主要终点及所有关键次要终点均已达成，25mg和50mg组分别实现39.3%和40.3%的安慰剂校正临床缓解率，疗效数据位居同类前列。部分投资者认为癌症病例更可能与患者年龄相关（NMSC病例平均年龄62岁，远高于试验人群平均42岁），市场前期反应或过度。当前股价自低位持续回升，反映多空博弈中买方力量阶段性占优。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.